What do systematic reviews say?

Osmotic‐release oral system methylphenidate vs placebo

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Low

Osmotic‐release oral system methylphenidate vs placebo

Osmotic‐release oral system methylphenidate probably leads to higher proportion of people withdrawing from treatment compared with placebo (moderate certainty).

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  RR 2.8 [1.14, 6.89]
  1 study · 33 participants
  Moderate

Osmotic‐release oral system methylphenidate vs placebo

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Low

Osmotic‐release oral system methylphenidate vs placebo

The review found no eligible studies for this question.

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Osmotic‐release oral system methylphenidate vs placebo

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Low

Osmotic‐release oral system methylphenidate vs placebo

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Moderate